Milan

• 7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors Ended
  2023-505284-36-00 4 2021-09-13 Advanced solid tumors
• A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec (RESPOND) Ended
  2023-505640-18-00 6 2021-09-02 Spinal Muscular Atrophy
• PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study Ended
  2024-518724-72-00 6 2021-09-02 Myocardial infarction with non-obstructive coronary arteries (MINOCA)
• A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended
  2024-512880-30-00 5 2021-08-27 Neovascular Age-related Macular Degeneration (wet AMD)
• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur
• Phase 2 First-Line ES-SCLC Platform Study Ended
  2023-506538-56-00 4 2021-08-12 First-line treatment of participants with extensive-stage small cell l
• A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended
  2024-511158-36-00 9 2021-08-05 Metastatic colorectal cancer
• A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan … Ended
  2024-512227-36-00 9 2021-07-28 Advanced solid tumors
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n … Ended
  2023-507431-37-00 5 2021-07-23 relapsing multiple sclerosis (RMS)
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma
• Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular C … Ended
  2023-505698-34-00 4 2021-07-13 Hepatocellular carcinoma
• A research study investigating troriluzole as a possible treatment for Obsessive Compulsive Disorder Ended
  2024-514585-39-00 5 2021-07-12 Obsessive Compulsive Disorder
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• A study designed to evaluate a modified Anti-Platelet Therapy (drugs that preventblood platelets from clotting) after implantation of a Fire … Ended
  2024-519854-35-00 6 2021-06-29 Acute Myocardial Infarction
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension Ended
  2022-500877-15-00 10 2021-06-25 Pulmonary arterial hypertension (PAH) in one of the following groups:
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M … Ended
  2023-506315-17-00 9 2021-06-25 Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naiv
• A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) Ended
  2022-500821-34-00 1 2021-06-15 Advanced Solid Tumors
• A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel … Ended
  2023-509155-14-00 4 2021-06-10 Peripheral T-cell Lymphoma
• European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended
  2022-500385-99-00 5 2021-06-03 SARS-CoV II infection (Coronavirus disease)
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease
• An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SA … Ended
  2023-510210-68-00 3 2021-05-26 Autoimmune haemolytic anaemia

Showing 2,209–2,232 of 2,391 trials